We conclude with a discussion of the knowledge gaps that must be addressed before incretin-based therapies can be properly deployed for maximum benefit in the treatment of obesity and T2DM
Patients who inject more frequently than weekly report higher rates of GI adverse events, particularly nausea and vomiting
Gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation are common across GLP-1 therapies
Vitamin B12 GLP-1 agonists can sometimes interfere with the absorption of vitamin B-12 in the gastrointestinal tract, potentially leading to lower levels of this essential nutrient over time
It's nice that light or air can never be added with this type of packaging, because vit C is sensitive to that
In SUSTAIN-6, wherein semaglutide (subcutaneous injection) was administered at 0.5 or 1 mg per week, MACE was also reduced by 26% in the semaglutide group compared with the placebo group (HR 0.74, 95% CI 0.580.95) as was stroke (HR 0.61, 95% CI 0.380.99) [17]